Appendix E: Measure Comparison by Race/Ethnicity, Three-Year Trend

Appendix E contains measure comparisons by race/ethnicity with three-year trends.

▼

Measures where higher is better:

Measures where lower is better:

•

Not enough data to report ***

Statistically significant higher rate than other races/ethnicities Statis

Statistically significant higher rate than other races/ethnicities

No statistically significant difference

	_	<u> </u>			
istically sig	gnificant lo	wer rate t	han other	races/	ethnicities

Statistically significant lower rate than other races/ethnicities

		Aı Indian//	nerica Alaska		As	ian		Black		1	aiian/Pa Islander		н	lispanic			White		Not Provided	/Other
		MY19	MY20	MY21	MY19 M	20 MY2	1 MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20 N	/Y21	MY19	MY20 M	Y21	MY19 MY20	MY21
Weight Assess & Counseling for Children & Adolescents (WCC), BMI, 3-11 Yrs	50% 0%	ä	* * *		•	•	•	•	•	•	•	-0	•	•	•	-	•	•	••	-0
Weight Assess & Counseling for Children & Adolescents (WCC), BMI, 12-17 Yrs	50% 0%	×	* * *		* :	* *	•	•	•		* * *				•	•	•	•	•	-
Weight Assess & Counseling for Children & Adolescents (WCC), BMI, Ttl	50% 0%	ĸ	* * *		•	•	•	•	-0	•	•	-0			•	V		•	• •	-0
Weight Assess & Counseling for Children & Adolescents (WCC), Nutrition, 3-11 Yrs	50% 0%	ä	* * *		•	-	•	-	•	•	•	-0	•		•	-	V	•	• •	•
Weight Assess & Counseling for Children & Adolescents (WCC), Nutrition, 12-17 Yrs	60% 40% 20%	ĸ	* * *		* :	* *	•	•	•		* * *		•		•	V	V	•	• •	-
Weight Assess & Counseling for Children & Adolescents (WCC), Nutrition, Ttl	50% 0%	ä	* * *		•	-	•	-	•		•	-0			•	V	V	•	• •	•
Weight Assess & Counseling for Children & Adolescents (WCC), Physical Activity, 3-11 Yrs	60% 40% 20%	ä	* * *		•		•	-•	•		•	-0			•	V		•	•	•
Weight Assess & Counseling for Children & Adolescents (WCC), Physical Activity, 12-17 Yrs	80% 40% 0%	×	* * *		* :	* *	•	•	•		* * *				•	V		•	••	-
Weight Assess & Counseling for Children & Adolescents (WCC), Physical Activity, Ttl	50% 0%	3	* * *		•	-	•	•	•		•	-0	•		•	V		•	• •	-0
Childhood Immunization Status (CIS), DTaP	100% 50% 0%	3	* * *			•	•			•	-0-	-			•	-	•	•	••	•

Measures where lower is better:

•

Not enough data to report *** No statistically significant difference

Statistically significant higher rate than other races/ethnicities Statistically significant lower rate than other races/ethnicities

Statistically significant higher rate than other races/ethnicities

Statistically significant lower rate than other races/ethnicities ▼

	American Indian/Alaska Native	Asian	Black	Hawaiian/Pacific Islander	Hispanic	White	Not Provided/Other
	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21
100% Childhood Immunization Status (CIS), IPV 50% 0%	* * *	•	••	00		V	00
Childhood Immunization Status (CIS), MMR 50%	* * *		••			▼▼	00
100% Childhood Immunization Status (CIS), HIB 50% 0%	* * *	•	•	00		▼▼	00
100% Childhood Immunization Status (CIS), Hepatitis B 50% 0%	* * *	•	•	•		V	00
100% Childhood Immunization Status (CIS), VZV 50% 0%	* * *		••	•		▼▼	00
Childhood Immunization Status (CIS), 50% Pneumococcal 0%	* * *	•	• •	• • •		V	•
100% Childhood Immunization Status (CIS), Hepatitis A 50% 0%	* * *		••	••		V	00
Childhood Immunization Status (CIS), 50% Rotavirus	* * *	•	• •	•		V	00
80% Childhood Immunization Status (CIS), Influenza 0%	* * *		•	•	•	V	
Childhood Immunization Status (CIS), 50% Combo 3 0%	* * *		• • •	• • •		T	00

Measures where higher is better:

Measures where lower is better:

•

Not enough data to report * * * No statistically significant difference Statistically significant higher rate than other races/ethnicities Statistically significant lower rate than other races/ethnicities Statistically significant higher rate than other races/ethnicities

Statistically significant lower rate than other races/ethnicities

	American Indian/Alaska Native		Black	Hawaiian/Pacific Islander	Hispanic	White	Not Provided/Other
	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21
Childhood Immunization Status (CIS), 50% Combo 7 0%			•	••		V	
Childhood Immunization Status (CIS), 40% Combo 10	* * *		• • •	00	•	V	
Immunizations for Adolescents (IMA), Meningococcal 0%	* * *	•	••	• • •		▼ ▼ ▼	00
100% Immunizations for Adolescents (IMA), Tdap 50% 0%	* * *	• • •	V • •	•		▼▼	••
60% Immunizations for Adolescents 40% (IMA), HPV 20%	* * *		•	• •		• • •	•
40% Lead Screening in Children (LSC) 20% 0%	* * *	• • •	• • •	00		• • •	•
60% Breast Cancer Screening (BCS) 40% 20%	•		• • •	00		V	
60% Cervical Cancer Screening (CCS) 40% 20%		••	••	• • •		▼▼	••
60% Chlamydia Screening (CHL), 16-20 Yrs 20%		••		00		▼▼	▼●
80% Chlamydia Screening (CHL), 21-24 Yrs 40% 0%	0-0-0	• • •		00		~ ~ ~	•

▼

Measures where higher is better:

Measures where lower is better:

•

Not enough data to report *** No statistically significant difference

Statistically significant higher rate than other races/ethnicities Statistically significant lower rate than other races/ethnicities

Statistically significant higher rate than other races/ethnicities .

Statistically significant lower rate than other races/ethnicities

		Aı Indian//	mericar Alaska			Asian			Black			aiian/Pa Islander			Hispani	с		White		Not Pr	rovide	d/Other
		MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21
Chlamydia Screening (CHL), Ttl	60% 40% 20%	•	•	-0	•	•				_	•	•	•				-	•		-	•	
Appropriate Testing for Pharyngitis (CWP), 3-17 Yrs	100% 50% 0%	A	•	-0	•	-•-	-0			•	•	•		•	•					•	•	•
Appropriate Testing for Pharyngitis (CWP), 18-64 Yrs	50% 0%	•	•	•	•	V		•	•	•	•	•	-0	•	•	•			-0	•		•
Appropriate Testing for Pharyngitis (CWP), Ttl	50% 0%	•	•	•	•	•	-			•	•	•	•	-	•					•	•	•
Use of Spirometry Testing in the Assess & Diagnosis of COPD (SPR)	30% 20% 10%	•	-0	-	•	•	-0	•	-	•	•		•	•	-		•	-	-0	•		
Pharmacotherapy Mgmt of COPD Exacerbation (PCE), Systemic Corticosteroid	80% 40% 0%	•	•	•		* * *		•	•	•		* * *		•	•	-0	•	•	•	•	•	•
Pharmacotherapy Mgmt of COPD Exacerbation (PCE), Bronchodilator	100% 50% 0%	V	-	•		* * *		•	•	•		* * *		•	•	-0	•	•	•	•	•	•
Asthma Medication Ratio (AMR), 5-11 Yrs	50% 0%	×	* * *			•	•	•	-	-0	•	•	-0	-	-	-	•				•	•
Asthma Medication Ratio (AMR), 12-18 Yrs	60% 40% 20%	ĸ	* * *		•	-	-0	•	•	•	•	-	•	•	•	•		•		•	•	•
Asthma Medication Ratio (AMR), 19-50 Yrs	80% 40% 0%	•	•	-0		•		•	Y	-	•	•	-0	•	-	•	•	•	•		•	•

Measures where higher is better:

Measures where lower is better:

Not enough data to report *** No statistically significant difference

Statistically significant higher rate than other races/ethnicities Statistically significant lower rate than other races/ethnicities

Statistically significant higher rate than other races/ethnicities

•

Statistically significant lower rate than other races/ethnicities ▼

		A Indian/	merica /Alaska			Asian			Black			aiian/F Islande			Hispanic	:		White		Not Pro	ovided/	/Other
		MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21
51-64 Yrs	0%	•	-0_	-		•		•	-	•	•		•	•	•		•	-	-0	•	•	-0
Asthma Medication Ratio (AMR), Ttl 4	0% 0% 0%	•		•				-	-	-	•		•	•			•	Y	-		•	•
Controlling High Blood Pressure (CBP) 4	0% 0% 0%		* * *		•	-	-0	-	•	•	•	•	-	•		-0	•	•	-0	•	•	-0
After a Heart Attack (PBH)	0%		* * *			* * *		•	•			* * *	:	•		-0	•	•	•	•	•	•
Statin Therapy for Patients With10Cardiovascular Disease (SPC),5Received Statin Therapy, 21-75 Yrs5	0% 0% 0%		* * *			•		•	•	•	•	•		•	•	-0	-		-	•	•	-0
Cardiovascular Disease (SPC), Received Statin Therapy, 40-75 Yrs	0% 0% 0%		* * *		•			-		-		•	-0	•	•	-0	•	•	-0	•	•	-0
Statin Therapy for Patients With Cardiovascular Disease (SPC), 5 Received Statin Therapy Ttl	0% 0% 0%	•	•	•				-	•	•	•	•		•	•	•	•	•	-	•	•	•
Adherence 80%, 21-75 Yrs (M)	0% 0%		* * *					-	•	-	•	•	-	-	•	•	•	•	•	•		•
Statin Therapy for Patients With Cardiovascular Disease (SPC), Statin 5 Adherence 80% 40-75 Yrs (F)	0% 0% 0%		* * *				•	•	•	•	•	•	-0	•	•	-0	•	•	-0	•		-0
Statin Therapy for Patients With Cardiovascular Disease (SPC), Statin 5 Adherence 80% Ttl	0% 0% 0%		* * *					-	•	-	•	•	•	-	-	•	•	-	•	•		•

Measures where higher is better:

Measures where lower is better:

Not enough data to report *** No statistically significant difference

- Statistically significant higher rate than other races/ethnicities
- Statistically significant lower rate than other races/ethnicities

		Aı Indian//	nerica Alaska			Asi	an			Black		1	aiian/P Islande			Hispan	c		White		Not Pr	rovided	/Other
		MY19	MY20	MY21	MY1	9 MY	20 1	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21
Comprehensive Dishetes Care (CDC)	50% 0%	*	* * *		•	-		•	•	•	•	•	•	•		•	-0	•	-0		•	•	•
Boor HbA1c Control (Lower score is	40% 20% 0%	×	* * *		•			•	•	•	•	•	•	•	•		-0	•	•	-0	•	-	•
Comprehensive Diabetes Care (CDC), HbA1c Control < 8.0%	60% 40% 20%	×	* * *					-	•		-0	•	-	•	•	-	0	-	-0	•		-	•
Comprehensive Diabetes Care (CDC), Eve Exam	60% 40% 20%	×	* * *						•	-•-	-0	•	•	•		-		-	-	-	•	•	•
Comprehensive Diabetes Care (CDC), Blood Pressure Control < 140/90 mm Hg	50% 0%	×	* * *		•			•	-	•	-0	•	-	-		•		-	•	-0	•	-	•
Statin Therapy for Patients With Diabetes (SPD), Received Statin Therapy	50% 0%	•	•						•	•					•	•		-	•				•
Statin Therapy for Patients With Diabetes (SPD), Statin Adherence 80%	50% 0%	•	•					•	-	-		•		•	-	-					•		•
Antidepressant Medication Mgmt	60% 40% 20%	•	•	•	•	-		-0	-	Ţ	-	•	-	-0	•	Y	-				•	-	•
Antidepressant Medication Mgmt	40% 20% 0%	•	•	•	•		-	-0	-	Ţ	-	-	•	-0	•	-						•	
Pollow-Up Care for Children Prescribed ADHD Medication (ADD),	60% 40% 20%	•		•	•			•	-		•	•	-	•	•	•	•				-	-	•

Measures where higher is better:

Measures where lower is better:

•

Not enough data to report *** No statistically significant difference

- Statistically significant higher rate than other races/ethnicities ▼
- Statistically significant lower rate than other races/ethnicities

		A Indian/	merica Alaska			Asian			Black		1	/aiian/ Island	/Pacific ler		Hispanio			White		Not Pro	ovided/	/Other
		MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY2	0 MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21
Follow-Up Care for Children Prescribed ADHD Medication (ADD), Continuation	60% 40% 20%		* * *			* * *	:	•	•	•		* *	*	•	•	•	•	•	-0	-	•	-0
Follow-Up after Hosp for Mental Illness (FUH), 30-Day FU, 6-17 Yrs	80% 40% 0%	•		-0		* * *	•	-	-	•		* *	*	•	-	•			•	•	-	-•
Follow-Up after Hosp for Mental Illness (FUH), 30-Day FU, 18-64 Yrs	60% 40% 20%	•		-	•	-	-0	-	-		•	-	•	•		•			•	-	-	
Follow-Up after Hosp for Mental Illness (FUH), 30-Day FU, Ttl	60% 40% 20%	•		•	-		-0	-	-	-	•	-	•			•				-	-	
Follow-Up after Hosp for Mental Illness (FUH), 7-Day FU, 6-17 Yrs	60% 40% 20%	•	-	•		* * *	:	•	-	•		* *	*	•		-	•	-	-	•	•	-
Follow-Up after Hosp for Mental Illness (FUH), 7-Day FU, 18-64 Yrs	40% 20% 0%	•		•	•	-	•	-	-		•			•	•	•			-	-	-	•
Follow-Up after Hosp for Mental Illness (FUH), 7-Day FU, Ttl	40% 20% 0%	•	•	•	•	-	-0	-	-		•					•			-	•	-	-
Follow-Up After ED Visit for Mental Illness (FUM), 30-Day FU, 6-17 Yrs	50% 0%	•	•	-0	•	-	0	•		-		* *	*	•	•		•			•	•	-0
Follow-Up After ED Visit for Mental Illness (FUM), 30-Day FU, 18-64 Yrs	60% 40% 20%	•	-	•	•	•	-	-	Ţ	-	•	•	•	•	-	•			•	•	•	-0
Follow-Up After ED Visit for Mental Illness (FUM), 30-Day FU, Ttl	60% 40% 20%	•	-	•	•	-	•	-	-	-	•	•	•			•				•	•	-0

Measures where lower is better:

Not enough data to report ***

Statistically significant higher rate than other races/ethnicities Stat

Statistically significant higher rate than other races/ethnicities

No statistically significant difference

tistically	significant	lower	rate tha	an other	races/	ethnicities

V Statistically significant lower rate than other races/ethnicities ▼

		American Indian/Alaska Native	Asian	Black	Hawaiian/Pacific Islander	Hispanic	White	Not Provided/Other
		MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21
Follow-Up After ED Visit for Mental Illness (FUM), 7-Day FU, 6-17 Yrs	60% 40% 20%	0-0-0	• • •	•	* * *	•		• • •
Follow-Up After ED Visit for Mental Illness (FUM), 7-Day FU, 18-64 Yrs	40% 20% 0%	• • •	• • •		00			•
Follow-Up After ED Visit for Mental Illness (FUM), 7-Day FU, Ttl	40% 20% 0%	0-0-0	•		••			
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 30-Day FU, 13-17 Yrs	20% 10%	* * *	* * *	* * *	* * *		00	* * *
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 30-Day FU, 18+ Yrs	30% 20% 10%	0-0-0	•	• • •		• •		• • • •
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 30-Day FU, Ttl	30% 20% 10%	0-0-0	•	• • •		•		• • • •
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 7-Day FU, 13-17 Yrs	10% 5%	* * *	* * *	* * *	* * *	• • •	• • •	* * *
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 7-Day FU, 18+ Yrs	20% 10% 0%	V		• • •		• •		V
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 7-Day FU, Ttl	20% 10% 0%	V	•	• •		•		
Follow-Up After High Intensity Care for SUD (FUI): 30-Day FU, 18-64 Yrs	60% 40% 20%	00	00	V V V	• • • •	A		• • •

Measures where higher is better:

Measures where lower is better:

•

Not enough data to report ***

Statistically significant higher rate than other races/ethnicities Statis

Statistically significant higher rate than other races/ethnicities

No statistically significant difference

tistically	significant	lower	rate	than	other	races/	ethnicities	

Statistically significant lower rate than other races/ethnicities ▼

		Indian/		Native		Asian			Black			aiian/Pa Islander			Hispanio			White		Not Provide	
		MY19	MY20	MY21	MY19	MY20 I	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19 MY2	0 MY21
Follow-Up After ED Visit for Mental Illness (FUM), 7-Day FU, 6-17 Yrs	60% 40% 20%	•	•	-	•	•	•	•	•	-		* * *		•	Ţ	•	•		_	• •	
Follow-Up After ED Visit for Mental Illness (FUM), 7-Day FU, 18-64 Yrs	40% 20% 0%	•	•	-0	•	•		-	-	-	•	-	-0	•	-	-				•	•
Follow-Up After ED Visit for Mental Illness (FUM), 7-Day FU, Ttl	40% 20% 0%	•	•	-0	•	•	-	•	-	-	•	-0	•		-	•				-	•
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 30-Day FU, 13-17 Yrs	20% 10%	;	* * *		*	* * *			* * *			* * *		•			•	-0	-0	* *	*
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 30-Day FU, 18+ Yrs	30% 20% 10%	•	-	-0	•	•	-	—	¥	V	•	_	•	•	•	•				• •	•
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 30-Day FU, Ttl	30% 20% 10%	•	•	•	•	-	-	-	V		•	_	•	•	•	-0				• •	•
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 7-Day FU, 13-17 Yrs	10% 5%		* * *		7	* * *			* * *			* * *		•	•	•	•	•	-0	* *	*
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 7-Day FU, 18+ Yrs	20% 10% 0%	•	-	•	•		-	•	Ţ	-	•	_	-	•	•	•				-	•
Follow-Up After ED Visit for Alcohol & Other Drug Abuse Dependencies (FUA), 7-Day FU, Ttl	20% 10% 0%	•	•	•	•	•	-	•	Ţ		-	-	-	•	V	-				•	•
Follow-Up After High Intensity Care for SUD (FUI): 30-Day FU, 18-64 Yrs	60% 40% 20%	•	•	•	•	•	•	—	•	-	•	•	•		•	•	•			••	

* * *

* * *

-

T.

.

* * *

-

-0

Measures where lower is better:

.

* * *

* * *

-

* * *

-

. -

-0

-0

-0

* * *

.

Not enough data to rep

Who Are Using Antipsychotic

Diabetes Monitoring for People With

Cardiovascular Monitoring for People 40%

Diabetes & Schizophrenia (SMD)

with Cardiovascular Disease &

Adherence to Antipsychotic

Medications for Individuals With

Adolescents on Antipsychotics

Metabolic Monitoring for Children &

(APM), Blood Glucose Testing, 1-11

Schizophrenia-á(SMC)

Schizophrenia (SAA)

Yrs

0%

50%

0%

20%

50%

0%

40%

20%

* * *

* * *

* * *

Medication (SSD)

Not enough data to report ⁷ No statistically significant difference	•	, .	îcant higher rate than o îcant lower rate than o	other races/ethnicities other races/ethnicities	_		te than other races/eth e than other races/eth	
		American Indian/Alaska Native	Asian	Black	Hawaiian/Pacific Islander	Hispanic	White	Not Provided/Other
		MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21
Follow-Up After High Intensity Care for SUD (FUI): 30-Day FU, Ttl	60% 40% 20%	••	00	• • •	• • •	A		• • •
Follow-Up After High Intensity Care for SUD (FUI): 7-Day FU, 18-64 Yrs	40% 20% 0%	• • •	••	• • •	• •		•	* -••
Follow-Up After High Intensity Care for SUD (FUI): 7-Day FU, Ttl	40% 20% 0%	• • •	• • •	• • •	• • •		•	••
Pharmacotherapy for Opioid Use Disorder (POD), 16-64 Yrs	30% 20% 10%	•-•	• • •	•		V		•-•
Pharmacotherapy for Opioid Use Disorder (POD), Ttl	30% 20% 10%	•-•	• • •	•		V		• • •
Diabetes Screening for People With Schizophrenia or Bipolar Disorder	50%		• • •	00	• • •	▼●		••

Comagine Health

▲

Measures where lower is better:

Not enough data to report *** No statistically significant difference

- Statistically significant higher rate than other races/ethnicities ▼
- Statistically significant lower rate than other races/ethnicities

		American Indian/Alaska Native	Asian	Black	Hawaiian/Pacific Islander	Hispanic	White	Not Provided/Other
		MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21
Metabolic Monitoring for Children & Adolescents on Antipsychotics (APM), Blood Glucose Testing, 12-17 Yrs	60% 40% 20%	• • •	* * *	• • •	* * *	••	00	••
Metabolic Monitoring for Children & Adolescents on Antipsychotics (APM), Blood Glucose Testing, Ttl	60% 40% 20%	• • •	• • •	00	0-0-0	00	00	• • •
Metabolic Monitoring for Children & Adolescents on Antipsychotics (APM), Cholesterol Testing, 1-11 Yrs	30% 20% 10%	* * *	* * *	00	* * *	00	00	00
Metabolic Monitoring for Children & Adolescents on Antipsychotics (APM), Cholesterol Testing, 12-17 Yrs	20%	00	* * *	00	* * *	00	00	••
Metabolic Monitoring for Children & Adolescents on Antipsychotics (APM), Cholesterol Testing, Ttl	40% 20% 0%	00	• • •	••	0-0-0	00	00	00
Metabolic Monitoring for Children & Adolescents on Antipsychotics (APM), Blood Glucose & Cholesterol Testing, 1-11 Yrs	30% 20% 10%	* * *	* * *	000	* * *	00	00	0-0-0
Metabolic Monitoring for Children & Adolescents on Antipsychotics (APM), Blood Glucose & Cholesterol Testing, 12-17 Yrs	30% 20% 10%	00	* * *	00	* * *	00	00	••
Metabolic Monitoring for Children & Adolescents on Antipsychotics (APM), Blood Glucose & Cholesterol Testing, Ttl	40% 20% 0%	00	• • •	• • •	0-0-0	00	00	00
Non-Recommended Cervical Cancer Screening in Adolescent Fs (NCS) (Lower score is better)	0%	•	••	V	••	▼		00
Appropriate Treat for Upper Respiratory Infection (URI), 3 Mnths-17 Yrs	100% 50% 0%	••	• • •			• • •	*	••

Measures where lower is better:

-

-

• • •

•

Not enough data to report ***

Statistically significant higher rate than other races/ethnicities Statistically significant lower rate than other races/ethnicities

-0

Statistically significant higher rate than other races/ethnicities

No statistically significant difference

		American		_	Hawaiian/Pacific			
		Indian/Alaska Native	Asian	Black	Islander	Hispanic	White	Not Provided/Other
		MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21	MY19 MY20 MY21
Substance Use Disorder (SUD) Treat	40%		• • •	- - -	• • •	V V		— — — —
Rate, 12-64 Yrs	20% 0%							
Substance Use Disorder (SUD) Treat	40%			•		•		
ate, 12-17 Yrs	20%							
	0% 40%							
Substance Use Disorder (SUD) Treat Rate, 18-64 Yrs	20%	-		• • •	• • •	— — —		— — — —
	0% 60%					.		
Mental Health Svc Rate, Broad	40%		• • •	• • • •	V			••
(MH-B), 6-64 Yrs	20%							
Mental Health Svc Rate, Broad	80%		T	• •	V	V		V V O
MH-B), 6-17 Yrs	40% 0%							
Mental Health Svc Rate, Broad	60% 40%		• • •	V V	— — —	V V		V V V
MH-B), 18-64 Yrs	20%							
	100%	••	•		0		V V	00
Appropriate Treat for Upper Respiratory Infection (URI), 18-64 Yrs	50%							
	0% 100%	•					V	
Appropriate Treat for Upper Respiratory Infection (URI), Ttl	50%		,					
	0%							
Avoidance of Antibiotic Treat for Acute Bronchitis/Bronchiolitis (AAB), 3 Mnths-17 Yrs	50%	• • • •	— — — —			00	V V	
	0%							

-

18-64 Yrs

Avoidance of Antibiotic Treat for

Acute Bronchitis/Bronchiolitis (AAB),

60%

40%

20%

.

Measures where higher is better:

Measures where lower is better:

•

Not enough data to report *** No statistically significant difference

- Statistically significant higher rate than other races/ethnicities
- Statistically significant lower rate than other races/ethnicities

		Aı Indian/	merican Alaska I			Asian			Black			aiian/Pa Islander		1	Hispani	C		White		Not Pro	ovided,	/Other
		MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21	MY19	MY20	MY21
Avoidance of Antibiotic Treat for Acute Bronchitis/Bronchiolitis (AAB), Ttl	50% 0%	•	•	-0	-	Ţ	-0										•	Ţ	-			
Use of Imaging Studies for Low Back Pain (LBP)	50% 0%	•	•	-0		•	•	•		•	•	•	•	•	•	•	-	•	-	•	•	-0
	10%																			-		
Use of Opioids at High Dosage (HDO) (Lower score is better)	5%	•	-	-	▼_	V				-		-	-0	•	V	-						
	0% 30%										-											
Use of Opioids from Multiple Prescribers (UOP) (Lower score is	20% 10%			-0	-	Ţ	V				-	-	-	•	V	•	•	•	•	▼	V	-•
better)	10%																					
Use of Opioids from Multiple Pharmacies (UOP) (Lower score is	10% 5%	•	-	-		_					•	-		•	-		•	-	_	•	-	
better)	0%																					
Use of Opioids from Multiple Prescribers & Multiple Pharmacies (UOP) (Lower score is better)	4% 2% 0%	•	•	-0	▼		_0				•	-	•	•	-		▼_	-	-0	•	-	-0
Risk of Continued Opioid Use (COU), At least 15 days, 18-64 Yrs (Lower score is better)	5%	•	•	-	V			•			-	Ţ	-	-	-	-				•		•
Risk of Continued Opioid Use (COU), At least 15 days, 65+ Yrs (Lower score is better)	0% 15% 10% 5%	3	* * *			* * *	:		* * *			* * *			* * *		•	-		:	* * *	
Risk of Continued Opioid Use (COU), At least 15 days, Ttl (Lower score is better)	5% 0%	•	•	-0	-			-	-		-	V		-	-		•			•		•
Risk of Continued Opioid Use (COU), At least 30 days, 18-64 Yrs (Lower score is better)	2% 0%	•	•		V	-		-	-		_	-		-		-				•		•

Measures where higher is better:

Measures where lower is better:

•

Not enough data to report ***

No statistically significant difference

- Statistically significant higher rate than other races/ethnicities
- Statistically significant lower rate than other races/ethnicities

		Indian/		a Native		Asian		MY10	Black	MV21	Hawaii Isla MY19 N	ander			Hispanio		MY19	White	MV21			/Other
At least 30 days, 65+ Yrs (Lower score is better)	2% 1%		* * *		WITIS	* * *		IVIT 19	* * *	WITZI		* *	11121		* * *	WITZI	•	11120	WI121	WITIS	* * *	WITZI
Risk of Continued Opioid Use (COU), At least 30 days, Ttl (Lower score is better)	0% 4% 2% 0%	•	-		_	-		_	-			—	_		_					•		•
Adults' Access to Preventive/Ambulatory Health Services (AAP) 20-44 Yrs	50% 0%	A	•	•	-	-		-		-		•	-						•	-	•	
Services (AAP) 45-64 Yrs	50% 0%	•			•	•	•	•	•	•	•	•	-				-		-	-		-
Adults' Access to Preventive/Ambulatory Health Services (AAP) 65+ Yrs	00% 50% 0%		* * *	:	-	-	•	•			-	•	•	V	-	•	-	-	•			
Services (AAP) Ttl	50% 0%				-		-	-			-	•							-	-	-	-
Dependence Treat (IET), Ttl: Initiation	10% 20% 0%		* * *	:		* * *	k	•	-	•	*	* *		-		-		-		•	•	•
Dependence Treat (IET), Ttl:	15% 10% 5%		* * *	:		* * *	k	•	-	•	*	* *		•	•	-•		-		•	-	•
Dependence Treat (IET), Ttl: Initiation of AOD Treat: 18+ Yrs	40% 20% 0%	•	-	-0	•		-	-	Y	-	•	•	•	•	V	•			•	•		•
Dependence Treat (IET), Ttl: 1	15% 10% 5%	•	•	•	•	•	-0	-	-		•	•	-	-	•	-			-	•		-

Measures where lower is better:

•

Not enough data to report * * *

I&E of Alcohol & Other Drug

of AOD Treat: Ttl

Dependence Treat (IET), Ttl: Initiation

Statistically significant higher rate than other races/ethnicities

Statistically significant higher rate than other races/ethnicities Statistically significant lower rate than other races/ethnicities •

Statis No statistically significant difference

American

Indian/Alaska Native

40%

20%

	-	-			
stically	significant	lower rate	than other	races/ethnicities	5



	0%							
I&E of Alcohol & Other Drug Dependence Treat (IET), Ttl: Engagement of AOD Treat: Ttl	15% 10% 5% 0%	00	• •	•		• • •		•
Prenatal & Postpartum Care (PPC), Timeliness of Prenatal Care	80% 60% 40% 20%	* * *	••	••	•	00	00	
Prenatal & Postpartum Care (PPC), Postpartum Care	80% 60% 40% 20%	* * *	••	• • •	• • •		00	• • •
Use of First-Line Psychosocial Care for Children & Adolescents on Antipsychotics (APP), 1-11 Yrs	60% 40% 20% 0%	* * *	* * *	* * *	* * *	0-0-0	•	* * *
Use of First-Line Psychosocial Care for Children & Adolescents on Antipsychotics (APP), 12-17 Yrs	80% 60% 40% 20%	* * *	* * *	••	* * *	00	0-0-0	0-0-0
Use of First-Line Psychosocial Care for Children & Adolescents on Antipsychotics (APP), Ttl	60% 40% 20% 0%	* * *	* * *	• • •	* * *	00	• • •	